Lucid Diagnostics (LUCD) Expected to Post Quarterly Earnings on Thursday

Lucid Diagnostics (NASDAQ:LUCD) is expected to announce its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Lucid Diagnostics to post earnings of ($0.06) per share and revenue of $1.63 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). The company had revenue of $1.47 million for the quarter, compared to analyst estimates of $1.43 million. On average, analysts expect Lucid Diagnostics to post ($0.29) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.

Lucid Diagnostics Price Performance

Shares of LUCD stock opened at $0.42 on Tuesday. The firm has a 50-day moving average price of $0.65 and a 200 day moving average price of $1.00. Lucid Diagnostics has a twelve month low of $0.30 and a twelve month high of $1.63.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. BTIG Research reaffirmed a “buy” rating on shares of Lucid Diagnostics in a research note on Friday, October 23rd. Needham & Company LLC reiterated a “buy” rating on shares of Lucid Diagnostics in a report on Thursday, October 1st. Finally, Weiss Ratings lowered shares of Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Lucid Diagnostics currently has an average rating of “Moderate Buy” and an average price target of $4.19.

About Lucid Diagnostics

Lucid Diagnostics Inc (NASDAQ: LUCD) is a medical diagnostics company focused on improving the detection of esophageal disease. The company develops and commercializes diagnostic technologies intended to identify patients at elevated risk of esophageal cancer, particularly those with gastroesophageal reflux disease (GERD).

Lucid’s principal products include EsoGuard, a laboratory-developed DNA test that analyzes cells collected from the esophagus for molecular changes associated with Barrett’s esophagus and esophageal cancer risk, and EsoCheck, a swallowable, balloon-based device designed to collect cells from the esophageal lining.